Program Activities
New NIDA PAs and RFAs
On July 10, 2006, NIDA issued a Notice of Intent to Publish a Request for Applications for Mechanisms of Drug Abuse Interactions with HIV Neuropathogenesis (NOT-DA-06-016). The associated RFA is expected to be released in September 2006. This RFA will encourage a broad range of interdisciplinary research, using in vitro, animal and human approaches to address the basis of drug abuse and HIV interactions related to neuropathogenesis and neuropathology. This initiative was designed to broaden the AIDS research portfolio in both basic and clinical neuroscience.
On June 2, 2006, NIDA issued a Program Announcement (PA) entitled Drug Abuse Dissertation Research: Epidemiology, Prevention, Treatment, Services, and Women and Sex/Gender Differences (R36) PAR-06-446. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of drug abuse doctoral dissertation research in epidemiology, prevention, treatment, services, and women and sex/gender differences.
On July 10, 2006, NIDA issued a Program Announcement (PA) entitled Drug Abuse Dissertation Research: Epidemiology, Prevention, Treatment, Services, and Women and Sex/Gender Differences (R36) PAR-06-476. This is a reissuance of PAR-06-446, released June 2, 2006. The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of drug abuse doctoral dissertation research in epidemiology, prevention, treatment, services, and women and sex/gender differences.
On July 26, 2006, NIDA issued a Program Announcement (PA) entitled Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R01) PA-06-495. This Funding Opportunity Announcement (FOA) solicits health services research in conjunction with NIDA's Clinical Trials Network (CTN). The CTN is a research partnership between more than 150 community treatment programs (CTPs) and drug abuse researchers in multiple sites across the country. With its extensive network of providers serving diverse populations of drug users, the CTN provides an infrastructure for the investigation of (a) systems-level factors that facilitate practice improvement in community treatment programs, and (b) new research tools to facilitate higher quality health services research on practice improvement in drug abuse treatment.
On July 26, 2006, NIDA issued a Program Announcement (PA) entitled Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R21) PA-06-496. This Funding Opportunity Announcement (FOA) solicits health services research in conjunction with NIDA's Clinical Trials Network (CTN). The CTN is a research partnership between more than 150 community treatment programs (CTPs) and drug abuse researchers in multiple sites across the country. With its extensive network of providers serving diverse populations of drug users, the CTN provides an infrastructure for the investigation of (a) systems-level factors that facilitate practice improvement in community treatment programs, and (b) new research tools to facilitate higher quality health services research on practice improvement in drug abuse treatment.
On July 26, 2006, NIDA issued a Program Announcement (PA) entitled Health Services Research on Practice Improvement Utilizing Community Treatment Programs within the National Drug Abuse Clinical Trials Network (CTN) (R03) PA-06-497. This Funding Opportunity Announcement (FOA) solicits health services research in conjunction with NIDA's Clinical Trials Network (CTN). The CTN is a research partnership between more than 150 community treatment programs (CTPs) and drug abuse researchers in multiple sites across the country. With its extensive network of providers serving diverse populations of drug users, the CTN provides an infrastructure for the investigation of (a) systems-level factors that facilitate practice improvement in community treatment programs, and (b) new research tools to facilitate higher quality health services research on practice improvement in drug abuse treatment.
On August 9, 2006, NIDA issued a Program Announcement (PA) entitled Science Education Drug Abuse Partnership Award (R25) PAR-06-518. This Funding Opportunity Announcement (FOA) solicits Research Education (R25) grant applications to fund the development and evaluation of innovative model programs and materials for enhancing knowledge and understanding of neuroscience and the biology of drug abuse and addiction among K-12 students, the general public, health care practitioners, and other groups. The award provides support for the formation of partnerships between scientists and educators, media experts, community leaders, and other interested organizations for the development and evaluation of programs and materials that will enhance knowledge and understanding of science related to drug abuse. The intended focus is on topics not well addressed in existing efforts by educational, community or media activities.
On August 14, 2006, NIDA issued a Program Announcement (PA) entitled MDMA: Research Areas Needing More Emphasis (R03) PA-06-524. This Funding Opportunity Announcement (FOA) is intended to increase the scope of NIDA's MDMA (3,4-methylenedioxymethamphetamine) research portfolio in order to provide an optimally comprehensive, strategic, and balanced MDMA research program. Clinical and preclinical research is needed.
On August 14, 2006, NIDA issued a Program Announcement (PA) entitled MDMA: Research Areas Needing More Emphasis (R21) PA-06-525. This Funding Opportunity Announcement (FOA) is intended to increase the scope of NIDA's MDMA (3,4-methylenedioxymethamphetamine) research portfolio in order to provide an optimally comprehensive, strategic, and balanced MDMA research program. Clinical and preclinical research is needed.
PAs and RFAs Issued With Other NIH Components/Agencies
On May 15, NIDA, in conjunction with numerous other NIH components, issued a Program Announcment (PA) entitled Exploratory Innovations in Biomedical Computational Science and Technology (R21) PAR-06-411. The NIH is interested in promoting research and developments in computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. As defined here, biomedical computing or biomedical information science and technology includes database design, graphical interfaces, querying approaches, data retrieval, data visualization and manipulation, data integration through the development of integrated analytical tools, and tools for electronic collaboration, as well as computational and mathematical research including the development of structural, functional, integrative and analytical models and simulations.
On May 15, NIDA, in conjunction with numerous other NIH components, issued a Program Announcment (PA) entitled Innovations in Biomedical Computational Science and Technology (R01) PAR-06-410. The NIH is interested in promoting research and developments in computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. As defined here, biomedical computing or biomedical information science and technology includes database design, graphical interfaces, querying approaches, data retrieval, data visualization and manipulation, data integration through the development of integrated analytical tools, and tools for electronic collaboration, as well as computational and mathematical research including the development of structural, functional, integrative and analytical models and simulations.
On May 17, 2006, NIDA, in conjunction with numerous other NIH Institutes issued a Program Announcement (PA) entitled Exploratory/Developmental Bioengineering Research Grants (EBRG) [R21] PA-06-418. This Funding Opportunity Announcement (FOA) is intended to encourage innovation and high impact research. While minimal or no preliminary data are expected to be described in the application, applications should clearly indicate the significance of the proposed work and that the proposed research and/or development is scientifically sound, that the qualifications of the investigators are appropriate, and that resources available to the investigators are adequate.
On May 17, 2006, NIDA, in conjunction with numerous other NIH components issued a Program Announcement (PA) entitled Bioengineering Research Grants (BRG) [R01] PA-06-419. This funding opportunity will use the NIH R01 research grant award mechanism. The BRGs support multi-disciplinary research performed in a single laboratory or by a small number of investigators that applies an integrative, systems approach to develop knowledge and/or methods to prevent, detect, diagnose or treat disease or to understand health and behavior.
On May 17, NIDA in conjunction with numerous other NIH components, issued a Program Announcement (PA) entitled Brain Disorders in the Developing World: Research Across the Lifespan (R21) PAR-06-420. This Funding Opportunity Announcement (FOA) solicits applications for collaborative research projects, involving investigators in developed and developing countries, focusing on brain disorders throughout life relevant to developing nations. The collaborative research programs are expected to contribute to the long-term goal of building sustainable research capacity in developing countries to address neurological/ neurodevelopmental (including sensory, motor, cognitive and behavioral) function and impairment throughout life.
On May 19, 2006, NIDA and NIAAA jointly issued a Program Announcement (PA) entitled Complementary and Alternative Medicine for Substance and Alcohol Related Disorders (R03) PA-06-424. An important goal of this program is to identify, evaluate and develop safe and effective Complementary and Alternative Medicine therapies for the treatment of substance use disorders (SUD) and alcohol use disorders (AUD), including abuse or dependence on licit (alcohol and tobacco) and illicit drugs and for the treatment of neurological, psychiatric and medical consequences of drug and alcohol addiction.
On May 19, 2006, NIDA and NIAAA jointly issued a Program Announcement (PA) entitled Complementary and Alternative Medicine for Substance and Alcohol Related Disorders (R21) PA-06-425. An important goal of this program is to identify, evaluate and develop safe and effective Complementary and Alternative Medicine therapies for the treatment of substance use disorders (SUD) and alcohol use disorders (AUD), including abuse or dependence on licit (alcohol and tobacco) and illicit drugs and for the treatment of neurological, psychiatric and medical consequences of drug and alcohol addiction.
On May 22, 2006, NIDA and NIMH jointly issued a Program Announcment (PA) entitled Therapeutics Development for HIV/AIDS-Associated Neuropsychological Disorders (SBIR [R43/R44]) PA-06-432. This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for the development of therapeutics to treat HIV/AIDS-associated mental and neurological disorders. The NIMH Center for Mental Health Research on AIDS (CMHRA) and NIDA encourage the discovery and development of novel agents, methods, biomarkers and drug delivery technologies that can directly or indirectly eliminate/eradicate HIV reservoirs in the brain. Novel assays/models of neurotoxicity and treatment efficacy measures are invited as are novel in vitro/vivo models that can be used for screening potential therapeutic agents.
On May 22, 2006, NIDA and NIMH jointly issued a Program Announcment (PA) entitled Therapeutics Development for HIV/AIDS-Associated Neuropsychological Disorders (STTR [R41/R42]) PA-06-433. This funding opportunity announcement (FOA) solicits Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) for the development of therapeutics to treat HIV/AIDS-associated mental and neurological disorders. The NIMH Center for Mental Health Research on AIDS (CMHRA) and NIDA encourage the discovery and development of novel agents, methods, biomarkers and drug delivery technologies that can directly or indirectly eliminate/eradicate HIV reservoirs in the brain. Novel assays/models of neurotoxicity and treatment efficacy measures are invited as are novel in vitro/vivo models that can be used for screening potential therapeutic agents.
On May 31, 2006, NIDA, in conjunction with a number of other NIH components, issued a Program Announcement (PA) entitled International Research Collaboration-Basic Biomedical (FIRCA-BB) [R03] PAR-06-436. This Funding Opportunity Announcement (FOA) facilitates collaborative basic biomedical research between scientists supported by the NIH and investigators in developing countries.
On May 31, 2006, NIDA, in conjunction with a number of other NIH components, issued a Program Announcement (PA) entitled International Research Collaboration-Behavioral, Social Sciences (FIRCA-BSS) [R03] PAR-06-437. This Funding Opportunity Announcement (FOA) facilitates collaborative behavioral and social science research between scientists supported by the NIH and investigators in developing countries.
On June 5, 2006, NIDA and NIMH jointly issued a Program Announcment (PA) entitled The Development of Frontal Cortex and Limbic System and Their Roles in Drug Abuse or Mental Health (R01) PA-06-444. This funding opportunity announcement (FOA) solicits research project (R01) grant applications to study the development of the frontal and prefrontal cortices, together with the subcortical areas of the limbic system, that play significant roles in mediating emotional and motivated behavior. This initiative is designed to support basic neuroscience research into the fundamental mechanisms of development of the frontal and prefrontal cortices, as well as the midbrain and basal forebrain structures that mediate a number of functions related to drug abuse and psychiatric disorders including the euphoric properties of drugs, actions of psychotherapeutic agents, and cognitive and emotional functions.
On June 5, 2006, NIDA and NIMH jointly issued a Program Announcment (PA) entitled The Development of Frontal Cortex and Limbic System and Their Roles in Drug Abuse or Mental Health (R21) PA-06-445. This funding opportunity announcement (FOA) solicits exploratory/developmental (R21) grant applications to study the development of the frontal and prefrontal cortices, together with the subcortical areas of the limbic system, that play significant roles in mediating emotional and motivated behavior. This initiative is designed to support basic neuroscience research into the fundamental mechanisms of development of the frontal and prefrontal cortices, as well as the midbrain and basal forebrain structures that mediate a number of functions related to drug abuse and psychiatric disorders including the euphoric properties of drugs, actions of psychotherapeutic agents, and cognitive and emotional functions.
On June 12, 2006, NIDA, in conjunction with numerous other NIH Institutes issued a Program Announcement (PA) entitled Bioengineering Research Partnerships (BRP) [R01] PAR-06-459. Through this PA, participating Institutes and Centers of the NIH invite applications for R01 awards to support Bioengineering Research Partnerships (BRPs) for basic, applied, and translational multi-disciplinary research that addresses important biological or medical research problems.
On July 7, 2006, NIDA and NIMH jointly issed a Program Announcement (PA) entitled Research on Rural Mental Health and Drug Abuse Dirorders (R01) PA-06-478. The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications to stimulate research on mental health and/or drug abuse problems in rural and frontier communities that will: (1) enhance understanding of structural (including community risk and resilience factors) cultural, and individual factors that may enhance the provision and utilization of prevention and treatment services in these communities; and (2) generate knowledge to improve the organization, financing, efficiency, effectiveness, quality and outcomes of mental health and drug abuse services for diverse populations in rural and frontier populations.
On July 14, 2006, NIDA, in collaboration with NIAAA and the National Center for Complementary and Alternative Medicine (NCCAM) issued a Program Announcement (PA) entitled Behavioral and Integrative Treatment Development Program (R01) PA-06-486. This Funding Opportunity Announcement (FOA) invites applications for grant funding to support behavioral and integrative treatment research that will have a meaningful impact on improving treatment for drug and alcohol abuse and dependence.
On July 14, 2006, NIDA, in collaboration with NIAAA and the National Center for Complementary and Alternative Medicine (NCCAM) issued a Program Announcement (PA) entitled Behavioral and Integrative Treatment Development Program (R21) PA-06-487. This Funding Opportunity Announcement (FOA) invites applications for grant funding to support behavioral and integrative treatment research that will have a meaningful impact on improving treatment for drug and alcohol abuse and dependence.
On July 14, 2006, NIDA, in collaboration with NIAAA and the National Center for Complementary and Alternative Medicine (NCCAM) issued a Program Announcement (PA) entitled Behavioral and Integrative Treatment Development Program (R03) PA-06-488. This Funding Opportunity Announcement (FOA) invites applications for grant funding to support behavioral and integrative treatment research that will have a meaningful impact on improving treatment for drug and alcohol abuse and dependence.
On June 16, 2006, NIDA, in collaboration with numerous other NIH components, issued a Program Announcement (PA) entitled Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grants (T32) PA-06-468. The primary objective of this program is to prepare qualified individuals for careers that have a significant impact on the health-related research needs of the Nation.
On July 21, 2006, NIDA, in collaboration with numerous other NIH components, issued a Program Announcement (PA) entitled Ruth L. Kirschstein National Research Service Award (NRSA) for Individual Predoctoral Fellowships (F31) to Promote Diversity in Health-Related Research PA-06-481. The primary objective of this program is to help ensure that diverse pools of highly trained scientists will be available in appropriate research areas to carry out the Nation's biomedical, behavioral, health services or clinical research agenda.
On August 7, 2006, NIDA, in conjunction with a number of other NIH Institutes, issued a Program Announcement (PA) entitled Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) PA-06-461. This Funding Opportunity Announcement (FOA) invites NIH Exploratory/Developmental Grant (R21) applications from organizations/ institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.
On August 7, 2006, NIDA, in conjunction with a number of other NIH Institutes, issued a Program Announcement (PA) entitled Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R33) PA-06-462. This Funding Opportunity Announcement (FOA) invites Phase II Developmental (R33) grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.
On August 7, 2006, NIDA, in conjunction with a number of other NIH Institutes, issued a Program Announcement (PA) entitled Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21/R33) PA-06-463. This Funding Opportunity Announcement (FOA) invites Phased Innovation (R21/R33) grant applications from organizations/institutions that propose the development of novel radioligands for positron emission tomography (PET) or single photon computed tomography (SPECT) imaging in human brain, and that incorporate pilot or clinical feasibility evaluation in pre-clinical studies, model development, or clinical studies.
On August 7, 2006, NIDA, in conjunction with numerous other NIH components, issued a Program Announcement (PA) entitled Mentored Clinical Scientist Research Career Development Award (K08) PA-06-512. This award represents the continuation of a long-standing NIH program that provides support and "protected time" to individuals with a clinical doctoral degree for an intensive, supervised research career development experience in the fields of biomedical and behavioral research, including translational research.
On August 10, 2006, NIDA, in collaboration with numerous other NIH components, issued a Program Announcement (PA) entitled Networks and Pathways Collaborative Research Projects (R01) PA-06-522. This announcement solicits applications for research project grants that will leverage and complement ongoing technology development being pursued in the National Technology Centers for Networks and Pathways (TCNPs), a program of the NIH Roadmap for Medical Research. These collaborative projects should focus either on addressing a challenging biological problem using the technology developed in one or more of the TCNPs, or on the development of technology that will complement that which is being developed in the centers.
On August 10, 2006, NIDA, in collaboration with numerous other NIH components, issued a Program Announcement (PA) entitled Dissemination and Implementation Research in Health (R03) PAR-06-520. This funding opportunity announcement (FOA) encourages investigators to submit research grant applications that will identify, develop and refine effective and efficient methods, structures and strategies that test models to disseminate and implement research-tested health behavior change interventions and evidence-based prevention, early detection, diagnostic, treatment and quality of life improvement services into public health and clinical practice settings.
On August 10, 2006, NIDA, in collaboration with numerous other NIH components, issued a Program Announcement (PA) entitled Dissemination and Implementation Research in Health (R21) PAR-06-521. This funding opportunity announcement (FOA) encourages investigators to submit research grant applications that will identify, develop and refine effective and efficient methods, structures and strategies that test models to disseminate and implement research-tested health behavior change interventions and evidence-based prevention, early detection, diagnostic, treatment and quality of life improvement services into public health and clinical practice settings.
On August 15, 2006, NIDA, in collaboration with numerous other NIH components, issued a Program Announcment (PA) entitled Independent Scientist Award (K02) PA-06-527. In general, the Independent Scientist Award provides support for newly independent scientists who can demonstrate a need for a period of intensive research focus as a means of enhancing their research careers. The K02 is intended to foster the development of outstanding scientists and to enable them to expand their potential to make significant contributions to their field of research. The participating NIH components have distinctive guidelines, requirements, salary and research support levels provided under the auspices of this announcement.
On August 21, 2006, NIDA, in collaboration with NIMH and NINDS, issued a Program Announcement (PA) entitled Preclinical Therapeutics Development for NeuroAIDS (R21) PA-06-528. Through this PA, participating Institutes invite applications proposing novel models of HIV-related central or peripheral nervous system damage that can be used to screen for compounds showing promise as treatments in the patient population.
On August 21, 2006, NIDA, in collaboration with NIMH and NINDS, issued a Program Announcement (PA) entitled Preclinical Therapeutics Development for NeuroAIDS (R03) PA-06-529. Through this PA, participating Institutes invite applications proposing novel models of HIV-related central or peripheral nervous system damage that can be used to screen for compounds showing promise as treatments in the patient population.
On August 2, 2006, NIDA and a number of other NIH Institutes issued a Program Announcement (PA) entitled Parenting Capacities and Health Outcomes in Youth and Adolescents (R21) PA-06-530. This funding opportunity announcement solicits Exploratory/ Developmental (R21) grant applications from applicant organizations aimed at increasing the parenting skills and capacities of parents and caregivers to improve the health outcomes of their young and adolescent children.
On August 22, 2006, NIDA, in conjunction with numerous other NIH Institutes, issued a Program Announcement (PA) entitled Functional Links Between the Immune System, Brain Function and Behavior (R21) PA-06-533. This FOA requests research grant applications to study neuroimmune molecules and mechanisms involved in regulating normal and pathological central nervous system (CNS) function.
On August 23, 2006, NIDA in conjunction with numerous other NIH components issued a Program Announcment (PA) entitled Innovations in Biomedical Computational Science and Technology Initiative (STTR [R41/42]) PAR-06-534. This funding opportunity announcement (FOA) solicits Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) that propose innovative research in biomedical computational science and technology to promote the progress of biomedical research.
On August 23, 2006, NIDA in conjunction with numerous other NIH components issued a Program Announcment (PA) entitled Innovations in Biomedical Computational Science and Technology Initiative (SBIR [R43/44]) PAR-06-535. This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose innovative research in biomedical computational science and technology to promote the progress of biomedical research.
On June 2, 2006, NIDA, in conjunction with NIMH and NIAAA, issued a Program Announcement (PA) entitled Research on the Reduction and Prevention of Suicidality (R01) PA-06-438. The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications for research that will reduce the burden of suicidality (deaths, attempts, and ideation). The intent is to intensify investigator-initiated research on the topic, to attract new investigators to the field, and increase interdisciplinary approaches to developing effective strategies to reduce suicidality.
On June 2, 2006, NIDA, in conjunction with NIMH and NIAAA, issued a Program Announcment (PA) entitled Risk Factors for Psychopathology Using Existing Data Sets (R01) PA-06-439. The purpose of this Funding Opportunity Announcement (FOA) is to invite grant applications involving extensive and innovative use of existing data sets to study the development of psychopathology, including alcohol and drug abuse, in order to guide the development of preventive and treatment intervention strategies.
On June 12, 2006, NIDA, in collaboration with a number of other NIH components and the FDA, issued an RFA entitled Specialized Centers of Interdisciplinary Research (SCOR) on Sex and Gender Factors Affecting Women's Health (P50) RFA-OD-06-003. Through this RFA, the Office of Research on Women's Health and other participating Institutes and the FDA seek to offer the Specialized Centers of Interdisciplinary Research (SCOR) on Sex and Gender Factors Affecting Women's Health for the second time. These centers will provide opportunities for interdisciplinary approaches to advancing studies on how sex and gender factors affect women's health. Each SCOR should develop a research agenda bridging basic and clinical research on sex/gender factors underlying a health issue that affects women.
On June 13, 2006, NIDA, in conjunction with numerous other NIH components and the Agency for Healthcare Research and Quality (AHRQ) issued an RFA entitled Building Interdisciplinary Research Careers in Women's Health (K12) RFA-OD-06-004. Through this RFA the ORWH and its cosponsors invite institutional career development award applications for Building Interdisciplinary Research Careers in Women's Health (BIRCWH) Career Development Programs. These programs will support mentored research career development of junior faculty members, known as BIRCWH Scholors, who have recently completed clinical training or postdoctoral fellowships, and who will be engaged in interdisciplinary basic, translational, behavioral, clinical, and/or health services research relevant to women's health or sex/gender factors. The goal of this initiative is to increase the number of skills of investigators through a mentored research and career development experience leading to an independent scientific career that will benefit the health of women, including research on sex/gender similarities or differences in biology, health or disease.
On August 18, 2006, NIDA, in collaboration with numerous other NIH components, issued An RFA entitled Clinical Research Education and Career Development (CRECD) in Minority Institutions (R25) RFA-RR-06-003. This Funding Opportunity Announcement (FOA) is intended to encourage both current CRECD awardee institutions in the final year of funding and eligible institutions that have not received previous CRECD award to apply. These awards are intended to support development and implementation of curriculum-dependent programs in minority institutions to train selected doctoral or postdoctoral candidates in clinical research leading to a Masters of Science in Clinical Research or a Master of Public Health in a clinically relevant area. A successful program will result in an accredited master's degree program to produce trained clinical researchers who can become part of translational and/or patient-oriented research projects.
Other Program Activities
CTN Update
On August 3, 2006, NIDA/CCTN released RFA-DA-07-001, http://grants.nih.gov/grants/ guide/rfa-files/RFA-DA-07-001.html, Announcement of a Limited Competition of THE NATIONAL DRUG ABUSE TREATMENT CLINICAL TRIALS NETWORK (U10). This RFA announces a limited competition for competitive cooperative agreement renewal applications from established clinical investigators to participate in the National Drug Abuse Treatment Clinical Trials Network (CTN). The competition is restricted to only those institutions that currently house an existing, active Node in the CTN. As a nation-wide partnership among drug abuse treatment providers, researchers, and NIDA staff, the mission of the CTN is to improve the quality of drug abuse treatment throughout the country using science as the vehicle.
A total of 26 protocols and surveys have been initiated since 2001. A total of 11,778 participants were screened and 7,177 enrolled in studies as of July 27, 2006. Of these studies, 12 have completed enrollment and locked the data; eight completed enrollment and are in the follow-up phase; five are currently enrolling; and one is in the protocol development phase.
Twelve protocols have locked the data:
Protocol CTN 0001, Buprenorphine/Naloxone versus Clonidine for Inpatient Opiate Detoxification
Protocol CTN 0002, Buprenorphine/Naloxone versus Clonidine for Outpatient Opiate Detoxification
Protocol CTN 0003, Bup/Nx: Comparison of Two Taper Schedules
Protocol CTN 0004, MET (Motivational Enhancement Treatment) To Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse
Protocol CTN 0005, MI (Motivational Interviewing) To Improve Treatment Engagement and Outcome in Subjects Seeking Treatment for Substance Abuse
Protocol CTN 0006, Motivational Incentives for Enhanced Drug Abuse Recovery: Drug Free Clinics
Protocol CTN 0007, Motivational Incentives for Enhanced Drug Abuse Recovery: Methadone Clinics
Protocol CTN 0008, A Baseline for Investigating Diffusion of Innovation
Protocol CTN 0009, Smoking Cessation Treatment with Transdermal Nicotine Replacement Therapy in Substance Abuse Rehabilitation Programs
Protocol CTN 0011, A Feasibility Study of a Telephone Enhancement Procedure (TELE) to Improve Participation in Continuing Care Activities
Protocol CTN 0012, Characteristics of Screening, Evaluation, and Treatment of HIV/AIDS, Hepatitis C Viral Infection, and Sexually Transmitted Infections in Substance Abuse Treatment Programs
Protocol CTN 0016, Patient Feedback: A Performance Improvement Study in Outpatient Addiction Treatment
Eight protocols have ended new enrollment and are in either follow-up or data-lock phase:
Protocol CTN 0010 (Buprenorphine/Naloxone Facilitated Rehabilitation for Opioid Dependent Adolescents/Young Adults) began enrollment in July 2003. Recruitment ended January 31, 2006.
Protocol CTN 0013 (Motivational Enhancement Therapy to Improve Treatment Utilization and Outcome In Pregnant Substance Abusers) began enrollment in November 2003 and reached its enrollment target of 200 randomized participants.
Protocol CTN 0015 (Women's Treatment for Trauma and Substance Use Disorder: A Randomized Clinical Trial) began in March 2004. The study reached its enrollment target in October 2005, and follow-up continues until fall 2006.
Protocol CTN 0017 (HIV and HCV Intervention in Drug Treatment Settings). The study began enrollment in November 2004 and enrolled at eight community treatment sites across five Nodes. Enrollment ended in February 2006; follow-up will be complete in summer 2006.
Protocol CTN 0018 (Reducing HIV/STD Risk Behaviors: A Research Study for Men in Drug Abuse Treatment) began enrolling in April 2004 and reached its target enrollment in September 2005. Follow-up will be complete in summer 2006.
Protocol CTN 0019 (Reducing HIV/STD Risk Behaviors: A Research Study for Women in Drug Abuse Treatment) began enrollment in May 2004 and reached its target in October 2005. Follow-up will continue until fall 2006.
Protocol CTN 0020 (Job Seekers Training for Substance Abusers). The protocol began enrollment in October 2004 and reached its enrollment target in February 2006. This study is also being conducted in a Navajo American Indian site, the Na'nizhoozhi Center, Inc. in Gallup, New Mexico, the first CTN study to be conducted there. Follow-up will continue through August 2006.
Protocol CTN 0021 (Motivational Enhancement Treatment to Improve Treatment Engagement and Outcome for Spanish-Speaking Individuals Seeking Treatment for Substance Abuse) began enrollment in November 2003 and reached its target goal in October 2005. The follow-up phase was completed in March 2006. This is the first Spanish-only protocol in the CTN.
Five protocols are currently enrolling:
Protocol CTN 0014, Brief Strategic Family Therapy for Adolescent Drug Abusers (BSFT), has been implemented at eight sites. The study has reached 80% enrollment. There currently are a total of 385 randomized participants.
Protocol CTN 0027, Starting Treatment with Agonist Replacement Therapies (START) is a randomized, open-label, multi-center study that was developed in collaboration with the Division of Pharmacotherapies & Medical Consequences of Drug Abuse (DPMCDA). Enrollment began in April 2006 and includes nine sites. Seven of the sites are actively recruiting. There are a total of 28 randomized participants.
Protocol CTN 0028, Randomized Controlled Trial of Osmotic-Release Methylphenidate (OROS MPH) for Attention Deficit Hyperactivity Disorder (ADHD) in Adolescents with Substance Use Disorders (SUD). Enrollment began March 17, 2006 in three sites; eight more sites should begin enrollment by September 2006.
Protocol CTN 0029, A Pilot Study of Osmotic-Release Methylphenidate (OROS MPH) in Initiating and Maintaining Abstinence in Smokers with Attention Deficit Hyperactivity Disorder (ADHD). This study is being carried out at six community treatment sites across five Nodes. There are a total of 58 randomized participants. Thirty-one participants have completed the active treatment phase and are in follow-up; 24 have completed the full study.
Protocol CTN 0030, Prescription Opioid Addiction Treatment Study (POATS) is a randomized 2-phase, open-label, multi-center study in outpatient treatment settings. Pre-screening began in May 2006. The study will be carried out in 12 sites. Seven participants have been randomized so far.
One protocol is in the development phase:
Protocol CTN 0031, Twelve-Step Facilitation: Evaluation of an Intervention to Improve Substance Abuse Treatment Outcomes by Increasing 12-Step Involvement.
In addition to the primary CTN trials, there are currently 17 funded studies supported by independent grants that use CTN studies as a platform.
IECRN Best Practices Report
A key NIH Roadmap initiative, Inventory and Evaluation of Clinical Research networks (IECRN) under which Westat Corporation profiled all the active clinical research networks, amounting to more than 270, studied the Best Practices of a selected number of networks for transportable knowledge to the operations of other networks. NIDA's Clinical Trials Network (CTN) was one of the thirty-one networks studied for its Best Practices. The IECRN Best Practices Report recognized NIDA CTN's accomplishments in building trust and collegiality between provider and researcher, an essential ingredient that is necessary in building a truly effective and integrated network. Additionally, the Report noted that the CTN had a "robust IT" program and used sophisticated technology through its data coordinating center.
NIDA's New and Competing Continuation Grants Awarded Since May 2006
Abdala, Nadia -- Yale University
Identifying HIV-Bridge-Population In STI Clinics, Russia
Anand, Rene -- Louisiana State University Health Ssciences Center, New Orleans
Modulation of Nicotinic Receptors By Cytosolic Proteins
Baldwin, Gayle C. -- University of California, Los Angeles
In Vivo Modeling of Methamphetamine and HIV Interactions
Balster, Robert L. -- Virginia Commonwealth University
The Behavioral Pharmacology of Phencyclidine
Blackard, Jason T. -- University of Cincinnati
Extrahepatic Replication & Viral Evolution of HCV During HCV/HIV Co-Infection
Blanco, Carlos -- New York State Psychiatric Institute
Smart: Improving Detection & Outcome of Psychiatric Comorbidity In Drug Treatment
Bond, Kimberly R. -- Mental Health Systems, Inc.
Enhancing Substance Abuse Treatment Services for Women Offenders
Bruno, John P. -- Ohio State University
High-Speed Detection of Stimulant-Induced Cortical ACH Release
Calsyn, Donald A. -- University of Washington
Prescription Opioid Misuse In a Large HMO
Chun, Jerold -- Scripps Research Institute
Receptor-Mediated S1p Signaling In the Embryonic Brain
Clark, Pamela I. -- Battelle Centers/Public Health Research & Evaluation
Physiologic Impact of Variation In Smoke Ph
Clatts, Michael C. -- National Development & Research Institutes
Situational Adaptations to Katrina and HIV Risk
Colder, Craig R. -- State University of New York at Buffalo
Motivation In Context: Risk For Early Substance Use
Colfax, Grant N. -- Public Health Foundation Enterprises
Mirtazapine To Reduce Methamphetamine Use Among MSM With High-Risk HIV Behaviors
Corsi, Karen F. -- University of Colorado Denver/Health Sciences Center, Aurora
Reduction of HIV Risk and Drug Use Among Out-of-Treatment Methamphetamine Users
Coviello, Donna M. -- University of Pennsylvania
Employment Intervention For Offenders
Crits-Christoph, Paul -- University of Pennsylvania
Patient Feedback Effectiveness Study
Cunningham, Kathryn A. -- University of Texas Medical Branch, Galveston
Neurobehavioral Pharmacology of Stimulants
Dewey, William L. -- Virginia Commonwealth University
The Role of Protein Kinase C In Opioid Tolerance
Donohue, Bradley C. -- University of Nevada, Las Vegas
An Outcome Study Involving Drug Abusing Mothers In Child Protective Services
Duncan, Erica J. -- Emory University
Acoustic Startle Reduction In Cocaine Dependence
Edwards, Robert H. -- University of California, San Francisco
Presynaptic Mechanisms of Neural Plasticity
Eiden, Rina D. -- State University of New York at Buffalo
Prenatal & Ets Exposure: Effects On Child Regulation
Feske, Ulrike -- University of Pittsburgh at Pittsburgh
Drug Abuse and Risky Sex In Borderline Personality
Galli, Aurelio A. -- Vanderbilt University
Amphetamine Regulation of Dopamine Transport
Gehricke, Jean G. -- University of California, Irvine
The Reinforcing Mechanisms of Smoking In Adult ADHD
Gelernter, Joel E. -- Yale University
Genetics of Cocaine Dependence
Golden, Matthew R. -- University of Washington
Development of a Methamphetamine Early Intervention
Gudelsky, Gary A. -- University of Cincinnati
Determinants and Consequences of MDMA Neurotoxicity
Heflinger, Craig A. -- Vanderbilt University
Substance Use Disorders & Service Use Among Rural Youth
Higgins, Stephen T. -- University of Vermont & State Agricultural College
Voucher-Based Incentives To Treat Pregnant Smokers
Hohmann, Andrea G. -- University of Georgia
An Endocannabinoid Mechanism for Stress-Induced Analgesia
Hooks, Shelly B. -- University of Georgia
Regulation of Dopamine Signaling By Striatal Rgs9-2; Mechanisms and Specificity
Iacono, William G. -- University of Minnesota, Twin Cities
Twin Study of ADHD, CD and Substance Abuse
Janda, Kim D. -- Scripps Research Institute
Immunopharmacotherapy For the Treatment of Cocaine Abuse
Kerns, John G. -- University of Missouri, Columbia
Anterior Cingulate, Prefrontal Cortex, and Conflict-Control Loop Theory
Killeen, Therese K. -- Medical University of South Carolina
Contingency Management/Adolescents With Marijuana Use Disorders
Kral, Alexander H. -- Research Triangle Institute
Correlates of Sexual Risk For HIV/STI Among Women Who Use Methamphetamine
Kranzler, Henry R. -- University of Connecticut School of Medicine and Dentistry
Genetics of Cocaine Dependence
Ling, Walter -- University of California, Los Angeles
Optimizing Outcomes Using Suboxone for Opiate Dependence
Loh, Horace H. -- University of Minnesota, Twin Cities
Neurochemical Basis of Opiate Addiction
Maier, Steven F. -- University of Colorado at Boulder
Stressor Controllability, Drugs of Abuse, and Serotonin
Malison, Robert T. -- Yale University
Drug Abuse, Sleep, and Cognition
Marlatt, G. Alan -- University of Washington
Efficacy of Mindfulness-Based Relapse Prevention
Martin, Eileen M. -- University of Illinois at Chicago
Cognitive Neuropsychology of HIV and Drug Abuse
Molina, Patricia E. -- Louisiana State University Health Sciences Center, New Orleans
Cannabinoid Effects on HIV/AIDS
Muehlbach, Britta -- Daytop Village
Technology Transfer: Promoting Change In The Therapeutic Community
Nestler, Eric J. -- University of Texas Southwest Medical Center, Dallas
Molecular Studies of Cocaine Action In Brain
O'Farrell, Timothy J. -- Harvard University Medical School
Opioid Patients: Behavioral Family Counseling and Naltrexone
Oliveto Beaudoin, Alison -- University of Arkansas Medical Sciences, Little Rock
Disulfiram for Cocaine Abuse In Methadone - Patients
Ondersma, Steven J. -- Wayne State University
Computer-Based Brief Intervention for Perinatal Drug, Alcohol, and Tobacco Abuse
Operario, Don -- University of Oxford
Gender, Relationship Dynamics, and HIV Risk
Pacula, Rosalie L. -- Rand Corporation
Economic Cost of Drug Use and Abuse
Parsons, Jeffrey T. -- Hunter College
Risk Reduction Intervention for Highly Vulnerable Emerging Adult Males
Pasternak, Gavril W. -- Sloan-Kettering Institute for Cancer Research
Biochemical Characterization of Opioid Receptors
Payne, Brian K. -- University of North Carolina, Chapel Hill
Neural Bases of Automatic and Controlled Affective Responses To Smoking Cues
Pearlson, Godfrey D. -- Yale University
Reward, Impulsivity and Cocaine Addiction: fMRI Studies
Porrino, Linda J. -- Wake Forest University Health Sciences
Early Exposure To Stimulants As A Risk Factor For Substance Abuse
Powell, Elizabeth M. -- University of Maryland Baltimore Professional School
Mechanisms of Forebrain Development
Ressler, Kerry J. -- Emory University
Molecular Regulation of GABA(A) Receptor Function In Amygdala
Reynolds, Brady -- Children's Research Institute
Impulsivity at Different Stages of Adolescent Smoking
Rigotti, Nancy A. -- Massachusetts General Hospital
Bupropion for Smoking Cessation In Postpartum Women
Roth, Michael D. -- University of California, Los Angeles
Vector-Based Generation of Monoclonal Antibodies Against The CB2 Receptor
Rush, Craig R. -- University of Kentucky
Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications
Sarafian, Theodore A. -- University of California, Los Angeles
Pulmonary Mitochondrial Injury Caused By Tetrahydrocannabinol
Sigmon, Stacey C. -- University of Vermont & State Agricultural College
Effective Treatment for Prescription Opioid Abuse
Slesinger, Paul A. -- Salk Institute for Biological Studies
Kir 3 Channel Subunits In Drug Abuse With GABAB Agonists
Small, Dana M. -- John B. Pierce Laboratory, Inc.
Interactions Between Nicotine Addiction and Food Reward
Smith, Sheryl S. -- SUNY Downstate Medical Center
Steroids and GABA: Physiology of Receptor Subunit Change
Sprague, Jeff R. -- University of Oregon
Positive Behavior Support and the Prevention of Adolescent Problems
Srivatsan, Malathi -- Arkansas State University
Nicotine and Development of Autonomic Neurons
Staley, Julie K. -- Yale University
Cognition, Tobacco Smoke and Nicotinic Receptor Occupancy
Stone, Laura S. -- University of Minnesota, Twin Cities
Proteomic Studies of Human Chronic Pain
Sweedler, Jonathan V. -- University of Illinois, Urbana-Champaign
Neuropeptides In the CNS With New Mass Spectrometric Sampling Protocols
Tangney, June P. -- George Mason University
Jail-Based Treatment To Reduce Substance Abuse, Recidivism and Risky Behavior
Tapert, Susan F. -- Veterans Medical Research Foundation, San Diego
fMRI and Cognition In Adolescent Cannabis Users
Tidey, Jennifer W. -- Brown University
Biological and Behavioral Mechanisms of Smoking In Schizophrenia
Todorov, Alexandre A. -- Washington University
Genetic Epidemiology of Opioid Dependence In Bulgaria
Toll, Lawrence R. -- SRI International
Subtype-Selective Nicotinic Receptor Ligands As Smoking Cessation Pharmacotherapy
Valdez, Avelardo -- University of Houston
Substance Use and Other Health Consequences Among Katrina Evacuees In Houston
Vulchanova, Lyudmila H. -- University of Minnesota, Twin Cities
Combined Proteomic and Functional Analysis of Sensory Neuron Plasticity
Walsh, Sharon L. -- University of Kentucky
Evaluation of Novel Treatments for Stimulant Dependence
Wang, Shaomeng -- University of Michigan at Ann Arbor
Design, Synthesis and Characterization of Dopamine Receptor 3 Ligands
Ward, Kenneth D. -- University of Memphis
Population-Based Assessment of Post-Katrina Smoking Relapse
Weissman, Daniel -- University of Michigan at Ann Arbor
Neural Substrates of Executive Control Revealed By fMRI
Westling, Erika H. -- University of California, Los Angeles
Pubertal Timing and Substance Use In Children and Adolescents: Gender Differences
Winters, Ken C. -- Treatment Research Institute, Inc.
Brief Intervention for Drug-Abusing Delinquents/Parents
Woody, George E. -- University of Pennsylvania
Methadone Maintenance and HIV Risk In Ukraine
Woolley, Catherine S. -- Northwestern University
Gender Differences In the Neural Circuitry of Addiction
Wu, Ping -- Columbia University Health Sciences
Ecstasy "Epidemic" and Youth: Trends, Comorbidity, Risk and Protective Factors
Xu, Jiansong -- University of California, Los Angeles
Cigarette Smoking and the Efficiency of the Frontoparietal Attentional Network
Yu, Lei -- Rutgers The State University of New Jersey, Newark
Human Genetic Polymorphism Impact In A Mouse Model
Zhang, Xiuwu -- Duke University
Conditional Interference-Mediated Reversal Cocaine Reinforcement
|
